首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFNA2 |
| Uniprot No | P01563 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-188aa |
| 氨基酸序列 | MFCDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQ KAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEAC VIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIM RSFSLSTNLQESLRSKE |
| 预测分子量 | 20 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Cloning and expression of human interferon-alpha 2 in Escherichia coli"**
*Author: Goeddel, D.V. et al.*
**摘要**: 该研究描述了人IFNA2基因在大肠杆菌中的克隆与高效表达，验证了重组蛋白的抗病毒活性及理化性质，为后续大规模生产奠定基础。
2. **"Structural analysis of recombinant human interferon-alpha 2 by NMR spectroscopy"**
*Author: Klaus, W. et al.*
**摘要**: 通过核磁共振技术解析IFNA2重组蛋白的三维结构，揭示其与受体结合的分子机制，为理性设计高活性干扰素类似物提供依据。
3. **"Recombinant IFN-α2 inhibits hepatocellular carcinoma growth via immunomodulation and anti-angiogenesis"**
*Author: Li, Y. et al.*
**摘要**: 证明IFNA2重组蛋白通过激活免疫细胞(如NK细胞)及抑制肿瘤血管生成，显著抑制肝癌小鼠模型中的肿瘤生长，提示其临床治疗潜力。
4. **"Comparative stability studies of recombinant interferon-alpha 2 formulations for therapeutic use"**
*Author: Braun, A. et al.*
**摘要**: 评估不同制剂条件下IFNA2重组蛋白的稳定性，发现聚山梨酯80等辅料可有效减少聚集，提升长期储存中的生物活性保留率。
**Background of IFNA2 Recombinant Protein**
Interferon alpha-2 (IFNA2) is a cytokine belonging to the type I interferon (IFN) family, which plays a critical role in innate immune responses against viral infections and tumorigenesis. Produced primarily by leukocytes, IFNA2 binds to the interferon-α/β receptor (IFNAR), activating the JAK-STAT signaling pathway. This triggers the expression of interferon-stimulated genes (ISGs) that mediate antiviral, antiproliferative, and immunomodulatory effects.
The recombinant IFNA2 protein is engineered through genetic cloning and expression in heterologous systems, such as *E. coli* or mammalian cells, ensuring high purity and biological activity. Unlike natural IFNA2. the recombinant form allows standardized production for research and therapeutic applications. Its structure typically includes a 165-amino acid chain with a conserved disulfide bond critical for stability and receptor interaction.
IFNA2 has been extensively studied for its therapeutic potential. Clinically, recombinant IFNA2 was historically used to treat chronic hepatitis B and C infections, hairy cell leukemia, and melanoma. However, its use has declined due to side effects (e.g., flu-like symptoms) and the advent of targeted therapies. Despite this, IFNA2 remains a vital tool in immunology research, particularly in studying interferon signaling, viral evasion mechanisms, and cancer immunotherapy strategies.
Recent studies also explore engineered IFNA2 variants or fusion proteins to enhance specificity and reduce toxicity. Additionally, recombinant IFNA2 serves as a reference standard in assays quantifying interferon activity or neutralizing antibodies in autoimmune diseases like systemic lupus erythematosus.
In summary, IFNA2 recombinant protein bridges foundational research and clinical innovation, offering insights into immune regulation while highlighting challenges in balancing therapeutic efficacy with safety.
×
